Apogee Therapeutics, Inc. (APGE)
Largest Insider Buys in Sector
APGE Stock Price History Chart
APGE Stock Performance
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Insider Activity of Apogee Therapeutics, Inc.
Over the last 12 months, insiders at Apogee Therapeutics, Inc. have bought $990,775 and sold $9.76M worth of Apogee Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Apogee Therapeutics, Inc. have bought $25.5M and sold $9.76M worth of stock each year.
Highest buying activity among insiders over the last 12 months: McKenna Mark C. (director) — $1.98M.
The last purchase of 20,000 shares for transaction amount of $990,775 was made by McKenna Mark C. (director) on 2024‑12‑12.
List of Insider Buy and Sell Transactions, Apogee Therapeutics, Inc.
| 2025-01-02 | Sale | Chief Medical Officer | 4,085 0.007% | $46.94 | $191,740 | +2.42% | ||
| 2024-12-12 | director | 20,000 0.0375% | $49.54 | $990,775 | +6.52% | |||
| 2024-12-11 | Sale | Chief Medical Officer | 4,540 0.0075% | $48.76 | $221,363 | -3.23% | ||
| 2024-12-04 | Sale | Chief Executive Officer | 15,000 0.0232% | $46.58 | $698,654 | -8.69% | ||
| 2024-12-04 | Sale | Chief Medical Officer | 6,665 0.0102% | $46.07 | $307,057 | -8.69% | ||
| 2024-11-06 | Sale | Chief Executive Officer | 15,000 0.0336% | $59.22 | $888,320 | -19.75% | ||
| 2024-11-06 | Sale | Chief Medical Officer | 6,665 0.0149% | $59.12 | $394,041 | -19.75% | ||
| 2024-10-02 | Sale | Chief Executive Officer | 40,000 0.0851% | $56.23 | $2.25M | -9.28% | ||
| 2024-10-02 | Sale | Chief Medical Officer | 6,665 0.0142% | $56.26 | $374,954 | -9.28% | ||
| 2024-09-04 | Sale | Chief Executive Officer | 40,000 0.0721% | $47.62 | $1.9M | +9.69% | ||
| 2024-09-04 | Sale | Chief Medical Officer | 6,665 0.012% | $47.56 | $316,969 | +9.69% | ||
| 2024-08-23 | Sale | Chief Financial Officer | 6,000 0.011% | $48.26 | $289,560 | +5.65% | ||
| 2024-08-07 | Sale | Chief Executive Officer | 40,000 0.0615% | $40.62 | $1.62M | +21.21% | ||
| 2024-08-07 | Sale | Chief Medical Officer | 7,335 0.0113% | $40.67 | $298,336 | +21.21% | ||
| 2023-07-13 | director | 2.94M 1.8926% | $17.00 | $50M | +50.02% |
Insider Historical Profitability
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | 1324487 2.2636% | $40.27 | 0 | 5 | |
| Dambkowski Carl | Chief Medical Officer | 255348 0.4364% | $40.27 | 0 | 7 | |
| Henderson Jane | Chief Financial Officer | 200871 0.3433% | $40.27 | 0 | 1 | |
| McKenna Mark C. | director | 20000 0.0342% | $40.27 | 1 | 0 | |
| Fairmount Funds Management LLC | director | 1992734 3.4056% | $40.27 | 1 | 0 | +50.02% |